CG Invites Co., Ltd. (KOSDAQ:083790)
South Korea · Delayed Price · Currency is KRW 871.00
-17.00 (-1.91%)
Oct 23, 2026, 3:30 PM KST
CG Invites Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 30,110 | 27,391 | 7,253 | 4,879 | 4,321 | 42,376 |
Revenue Growth | 185.45% | 277.64% | 48.67% | 12.90% | -89.80% | 40.21% |
Gross Profit Gross Profit Growth | -4,594 | -1,941 | -519.05 | 1,457 | 1,256 | 21,707 |
Operating Income Operating Income Growth | -24,304 | -23,614 | -39,178 | -32,119 | -23,092 | -6,846 |
Net Income Net Income Growth | 428.9 | -3,521 | -51,544 | -48,924 | -23,869 | -15,901 |
Earnings Per Share EPS Growth | 5.58 | -46.00 | -671.17 | -661.31 | -345.00 | -232.20 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Pharmaceutical Research Pharmaceutical Research Growth | 37,480 | 31,956 | 17,413 | 18,272 | 17,606 | 9,815 |
Invest Invest Growth | 774.91 | 744.29 | 1,594 | 863.08 | 597.83 | 7,861 |
Inter-Sectoral Adjustment Inter-Sectoral Adjustment Growth | - | -5,308 | -13,335 | -14,256 | -14,455 | -6,581 |
Other Other Growth | - | - | 1,581 | 9,413 | 18,890 | 14,812 |
Total Total Growth | 27,034 | 27,391 | 7,253 | 4,879 | 4,321 | 42,376 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 9,391 | 19,599 | 53,564 | 51,410 | 82,033 | 122,500 |
Total Debt Total Debt Growth | 45,438 | 46,461 | 53,457 | 39,123 | 70,199 | 74,723 |
Net Cash (Debt) Net Cash Growth | -36,047 | -26,861 | 106.82 | 12,287 | 11,835 | 47,777 |
Net Cash Growth | - | - | -99.13% | 3.82% | -75.23% | -38.11% |
Net Cash Per Share Net Cash Per Share Growth | -469.38 | -349.77 | 1.39 | 166.08 | 170.98 | 697.68 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -3,361 | -17,413 | -25,850 | -32,408 | -24,405 | -11,458 |
Capital Expenditures CapEx Growth | -1,263 | -2,671 | -9,138 | -23,236 | -14,632 | -10,607 |
Free Cash Flow Free Cash Flow Growth | -4,624 | -20,084 | -34,988 | -55,644 | -39,037 | -22,065 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -15.26% | -7.09% | -7.16% | 29.87% | 29.05% | 51.23% |
Operating Margin | -80.72% | -86.21% | -540.14% | -658.37% | -534.38% | -16.16% |
Pretax Margin | -61.18% | -74.60% | -690.20% | -1048.48% | -526.29% | -36.85% |
Profit Margin | 1.42% | -12.85% | -710.63% | -1002.81% | -552.35% | -37.52% |
FCF Margin | -15.36% | -73.32% | -482.38% | -1140.56% | -903.35% | -52.07% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 24, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 2.22 | 4.17 | 25.50 | 42.69 | 55.81 | 10.64 |